TrialHaematologica2015

Phase II trial of ponatinib in patients with chronic myeloid leukemia resistant to one previous tyrosine kinase inhibitor.

David Sanford et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.